Publications by authors named "D P McQuillen"
Background: There is limited evidence of association of nirmatrelvir-ritonavir (NMV-r) and incidence of postacute sequelae of SARS-CoV-2 infection (PASC) in patients with pre-existing cardiovascular disease (CVD).
Objectives: The objective of this study was to assess the association of NMV-r in nonhospitalized, vaccinated patients with pre-existing CVD and occurrence of PASC.
Methods: We conducted a retrospective cohort study utilizing the TriNetX research network, including vaccinated patients with pre-existing CVD who developed COVID-19 between December 2021 and December 2022.
In this article, we summarize findings from research conducted by the Johns Hopkins Center for Health Security and the Infectious Diseases Society of America to understand infectious disease (ID) workforce contributions to the coronavirus disease 2019 (COVID-19) response and their impacts. ID experts were found to have made diverse and unique contributions that went well beyond their usual responsibilities, with many spending several hours a week on these activities without additional compensation. These efforts were thought to not only build community resilience but also augment the ongoing public health response.
View Article and Find Full Text PDFArticle Synopsis
- Nirmatrelvir-ritonavir (NMVr) is a treatment for high-risk patients with symptomatic COVID-19, particularly those with cardiovascular issues who face greater risks from the virus.
- Ritonavir enhances NMVr's effectiveness but also inhibits key enzymes (CYP450, especially CYP3A4) and impacts drug transport, leading to potential interactions with cardiovascular medications.
- The review highlights the importance of understanding and managing these drug-drug interactions to prevent severe adverse effects in patients receiving NMVr along with other cardiovascular treatments.
Background: Treatment of coronavirus disease 2019 (COVID-19) with nirmatrelvir plus ritonavir (NMV-r) in high-risk nonhospitalized unvaccinated patients reduced the risk of progression to severe disease. However, the potential benefits of NMV-r among vaccinated patients are unclear.
Methods: We conducted a comparative retrospective cohort study using the TriNetX research network.